Top Picks
-
Pharma's Rare Disease Strategy
CNBC 12mo ago
-
Egypt army to launch Sinai kidnapping rescue
Top Picks 21m ago
-
Tsarnaev 'Friend' Killed by FBI Agent During Questioning
Top Picks 26m ago
-
Anthony Weiner for Mayor
Top Picks 43m ago
-
South Korea's combat ready helicopters
Top Picks 1h ago
-
IRS Official Pleads 5th Amendment
Top Picks 1h ago
-
Pope denies TV exorcism allegation
Top Picks 1h ago
-
Jodi Arias Says She 'Deserves A Second Chance'
Top Picks 1h ago
-
Say hello to Xbox One
Top Picks 1h ago
-
Blitzer asks atheist if she thanks God
Top Picks 2h ago
-
Missing Maine Teen May Have Known Accused Killer
Top Picks 2h ago
-
Third Night of Rioting in Stockholm
Top Picks 3h ago
-
Top Headlines: $1B Expected in Okla. Insurance Claims
Top Picks 3h ago
-
Cannes : Michael Douglas and Matt Damon alongside for "Behind the Candelabra"
Top Picks 3h ago
-
Apple's Tim Cook defends company in US Senate
Top Picks 3h ago
-
Syria Fires On Israeli Troops In Golan Heights
Top Picks 3h ago
Description
Investors have made big bets on drugs like Pfizer's Lipitor for cholesterol, Glaxo's Advair for Asthma, and many more. CNBC's Seema Mody reports rare diseases might be the next hot investment.
